Drug General Information |
Drug ID |
D01KIH
|
Former ID |
DNC003527
|
Drug Name |
4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H20N4
|
Canonical SMILES |
C1CN(CCN1CC2=CC=CC=C2)C3=CC=CC4=C3N=CN4
|
InChI |
1S/C18H20N4/c1-2-5-15(6-3-1)13-21-9-11-22(12-10-21)17-8-4-7-16-18(17)20-14-19-16/h1-8,14H,9-13H2,(H,19,20)
|
InChIKey |
ZNBOBGDGUIWKPE-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
D(4) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Nicotine pharmacodynamics pathway
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
|
Nicotine Activity on Dopaminergic Neurons
|
GPCRs, OtherWP58:Monoamine GPCRs
|
GPCRs, Other
|
References |
REF 1 | Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. |